GLUTATHIONE SODIUM ( DrugBank: Glutathione )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	2

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-005481-19-DK (EUCTR)	27/05/2014	27/05/2014	High Dose Antioxidant Treatment for Patients with Cystic Fibrosis	High Dose Antioxidant Treatment for Patients with Cystic Fibrosis	Cystic Fibrosis MedDRA version: 17.0;Level: LLT;Classification code 10068288;Term: Cystic fibrosis pulmonary exacerbation;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Mucolysin INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: ACETYLCYSTEINE Trade Name: Mucomyst INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: ACETYLCYSTEINE Trade Name: ACC INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: ACETYLCYSTEINE Trade Name: Tad INN or Proposed INN: GLUTATHIONE Other descriptive name: GLUTATHIONE SODIUM	Aarhus University Hospital	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Denmark
2	NCT00506688 (ClinicalTrials.gov)	July 2007	24/7/2007	Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients	Randomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis Patients	Cystic Fibrosis	Drug: reduced glutathione sodium salt;Drug: 0.9% normal saline (control)	Mukoviszidose Institut gGmbH	Cystic Fibrosis Foundation Therapeutics	Completed	8 Years	N/A	Both	153	Phase 2	Germany